Eli Lilly Stock Edges Up Ahead of Key Obesity and Diabetes Drug Data

Key Facts

1Eli Lilly stock recorded a slight increase of 0.23% to reach EUR 1043.40 in today's trading.

2The company achieved strong Q2 revenue growth of 47.70% to USD 22.97 billion, driven by Mounjaro and Zepbound sales.

3Investors are awaiting clinical trial results for obesity and diabetes treatments during the EASD meeting.

Eli Lilly stock recorded a slight increase of 0.23% to reach EUR 1043.40 in trading on September 30, 2026, AD HOC NEWS reported. Investors are awaiting clinical trial results for obesity and diabetes treatments scheduled for presentation during the European Association for the Study of Diabetes (EASD) meeting, including Phase 2 data for eloraTZP and Phase 3 results for retatrutide.

The company achieved strong Q2 revenue growth of 47.70% to USD 22.97 billion, driven by sales of Mounjaro and Zepbound. LLY closed at $1184.63 on September 29, 2026, as the company's market capitalization reached $1.1 trillion amid continued robust demand for its cardiometabolic drug portfolio.